THAR Stock Analysis: Buy, Sell, or Hold?
THAR - Tharimmune, Inc. Common Stock
$4.89
0.42 (9.40%)
▲
WAIT
LOW Confidence
Last Updated: January 30, 2026
Get Alerted When THAR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called THAR this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: THAR is 33.6% above fair value ($3.66). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: THAR is 33.6% above fair value ($3.66). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: THAR is currently trading at $4.89, which is considered extended relative to its 30-day fair value range of $2.55 to $3.66.
Technical Outlook: Technically, THAR is in a uptrend. The price is approaching resistance at $4.79. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.4% recently.
Market Sentiment: THAR has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $5.00 (+11.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, THAR is in a uptrend. The price is approaching resistance at $4.79. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.4% recently.
Market Sentiment: THAR has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $5.00 (+11.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$2.55 -
$3.66
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
55.3%
Protect Your Profits
THAR is technically overbought (RSI 81). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price significantly overextended (+33.6% above fair value)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+9.4%)
- BULLISH: Trading below Wall St target ($5.00)
- WARNING: Recommendation downgraded due to 33.6% overvaluation
Fair Price Analysis
30-Day Fair Range
$2.55 -
$3.66
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$2.71
Resistance Level
$4.79
Current Trend
Uptrend
Fundamental Context
Wall Street Target
$5.00
(+11.9%)
Last updated: January 31, 2026 2:04 AM ET
Data refreshes hourly during market hours. Next update: 3:04 AM
Data refreshes hourly during market hours. Next update: 3:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is THAR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$56 | 59 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$210 | 57 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 62 BUY |
|
ARVN
Arvinas Inc |
BUY
21 analysts |
$13 | 63 BUY |
Advanced THAR Option Strategies
Professional options setups generated by AI based on today's THAR price and gamma walls.
